ClinicalTrials.gg
Not yet recruitingNCT07736950RAZORUpdated Sep 30, 2026

A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma

A Phase 3 interventional study of Surovatamig and Involved Site Radiotherapy (ISRT) in Follicular Lymphoma, sponsored by Australasian Leukaemia and Lymphoma Group. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Australasian Leukaemia and Lymphoma Group · Phase 3, Interventional, and Treatment

How we know

Updated Sep 30, 2026Enrollment updatedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if surovatamig works better than standard of care involved-site radiotherapy (ISRT) with or without rituximab to treat patients with limited-stage follicular lymphoma. It will also learn about the safety of the drug.

The main questions it aims to answer is whether surovatamig can produce deeper and more durable responses, reduce the risk of disease relapse, and improve event-free survival.

Participants will:

1) Take surovatamig for 4 cycles. The first cycle will have a dose ramp up in 3 steps over a period of 14 days. Cycle 2-4 are for 28 days with drug administered every fortnight.

OR 2a) Undergo radiotherapy only for 3 weeks OR 2b) Radiotherapy + rituximab weekly for 6 doses (6 weeks)

Visit the clinic once every cycle, at the end of treatment, and be monitored every 3 months in year 1, every 6 months in year 2, and once a year from year 3-5 for checkups and tests.

Read the detailed description

What the study is about:

This study will evaluate whether surovatamig, a novel CD19 × CD3 bispecific T-cell engager, can improve outcomes for people with previously untreated, limited-stage nodal follicular lymphoma (FL). The trial will compare surovatamig with the current standard of care: involved-site radiotherapy (ISRT) with or without rituximab. The aim is to determine whether surovatamig can produce deeper and more durable responses, reduce the risk of disease relapse, and improve event-free survival.

Who is it for:

This study is for adults aged 18 years or older who have:

  1. Histologically confirmed classical follicular lymphoma (Grade 1-3a), Ann Arbor stage I or II nodal, non-bulky disease ( less or equal to 7 cm)
  2. PET-positive, measurable disease
  3. No prior lymphoma-directed therapy

Study details:

This is an international, Phase III randomised clinical trial. Participants will be randomised 1:1 on either Surovatamig (6 doses over 12 weeks with an additional triple step-up dosing schedule over 14 days for cycle 1) or to the standard of care treatment (Involved-Site Radiotherapy (24 Gy) with or without 6 doses of rituximab, according to each site's predefined standard). Participants will be followed up for 5 years after treatment to assess long-term outcomes.

A total of 140 participants will be enrolled across Australia, New Zealand, the United Kingdom, Ireland and Nordic countries.

What is hoped from it:

If successful, surovatamig could represent a new standard of care for patients with early-stage nodal follicular lymphoma that is highly effective, well-tolerated, non-radiation frontline option for patients with limited-stage FL.

02

Conditions studied

  • Follicular Lymphoma
03

In context

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

This study's planned enrollment of 140 is above the median of 48 across 1,505 interventional studies indexed under Lymphoma, Follicular.

Browse Lymphoma, Follicular studies →

Lead sponsor

Australasian Leukaemia and Lymphoma Group is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Sep 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients or their legally authorised representative must voluntarily sign and date an , approved by an HREC, prior to the initiation of any screening or trial specific procedures.
  2. Are willing and able to comply with procedures required in this protocol.
  3. Age 18 years and older at the time of signing the ICF
  4. Must have confirmed classical FL (previously Grade 1 to 3a FL) at the most recent representative tumour based on the local pathology report, according to the 5th edition of WHO Classification of Haematolymphoid Tumours (excluding cutaneous and duodenal FL).
  5. Must have Ann Arbor Stage I or II, nodal, non-bulky disease (maximum tumour diameter ≤7cm)
  6. Previously untreated disease (no prior systemic lymphoma-directed therapies)
  7. Has one or more target lesions:

    1. A PET/CT scan demonstrating PET-positive lesion(s), and
    2. ≥ 1 measurable nodal lesion (long axis > 1.5cm) on CT scan or MRI
  8. performance status 0-2
  9. Patient must have adequate haematologic function:

    1. ≥ 1.0 x 10\^9/L
    2. ≥ 90 g/L
    3. count ≥ 100 x 10\^9/L
  10. Patient must have adequate renal and liver function, unless values meeting the following criteria are related to lymphoma):

    1. Serum or ALT ≤ 3.0 ×
    2. Total ≤ 1.5 × ULN; subjects with Gilbert's syndrome may have total bilirubin levels > 1.5 x ULN, but conjugated (direct) bilirubin must be ≤ 2 x ULN
    3. Estimated ≥ 30 mL/min (as calculated by Cockcroft-Gault Formula)
  11. Patients of must have a negative serum pregnancy test 10 to 14 days prior to randomisation and again within 24 hours prior toC1D1. The pregnancy test must be sensitive to at least 25 mIU/ml.
  12. Women of childbearing potential must agree to practice at least 2 protocol-specified methods of , that are effective from 28 days prior to randomisation through at least 12 months after the last dose of trial therapy. Female patients of non-childbearing potential do not need to use birth control.
  13. Male patients who are sexually active with female partner(s) of childbearing potential, must agree, from 28 days prior to randomisation through 12 months after the last dose of trial therapy, to practice the protocol-specified contraception, particularly a latex or synthetic condom every time they have sexual intercourse with a partner of , even if they have undergone a successful vasectomy.

Exclusion criteria

Exclusion Criteria:

  1. Has a history of prior systemic therapy or radiotherapy for FL.
  2. Has prior or current Follicular large B-cell lymphoma (WHO 2022 classification), formerly Follicular lymphoma Grade 3B (WHO 2016 classification), histologic transformation to DLBCL or other aggressive lymphomas.
  3. Inadequately staged follicular lymphoma (unable to perform staging imaging or bone marrow trephine length totalling \<20mm)
  4. Known or suspected CNS involvement at screening based on clinical presentation or imaging findings.
  5. Prior exposure to surovatamig or a history of severe allergic or anaphylactic reactions to any component or of surovatamig
  6. Has had major surgery within 14 days prior to the first dose of trial intervention (excluding ) pr anticipation of the need for major surgery during trial intervention
  7. Relative for radiotherapy

    1. Non-rheumatoid collagen vascular disorders involving the potential radiation field
    2. Radiation field that may impact on Cardiac implantable electronic devices (CIEDs).
    3. Previous radiation therapy to the same site.
  8. cardiovascular disease, such as:

    1. Myocardial infarction within ≤ 12 weeks or stroke within 6 months prior to randomisation
    2. Screening 12-lead showing a baseline as corrected by Frederica's formula (QTcF) > 480 msec
    3. The following conditions within 3 months prior to randomisation:

    i. Uncontrolled unstable angina ii. (NYHA) Class III-IV congestive heart failure iii. Uncontrolled life-threatening cardiac arrhythmia iv. Other clinically significant ECG abnormalities in the opinion of the investigator

  9. History or presence of clinically relevant CNS pathology which, based on Investigator assessment, may prevent, limit, or confound the protocol-specified assessments of neurotoxicity. This may include current seizure disorder requiring therapy, major cerebrovascular ischemia/haemorrhage, aphasia, severe brain injuries, severe dementia, severe Parkinson's disease, or cerebellar disease. Note: patients with history of seizure disorder must have complete CNS workup
  10. History of other prior , except:

    1. Malignancy treated with curative intent and with no known active disease present for ≥2 years before the first dose of trial therapy and felt to be at low risk for recurrence by treating physician.
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    3. Adequately treated carcinoma in situ without evidence of disease.
    4. Localized prostate cancer, post-radical prostatectomy or with non-rising prostate-specific antigen levels \< 0.1 ng/mL.
  11. Current disease requiring therapy other than prednisolone \<10 mg daily (or equivalent)
  12. Known history of hemophagocytic lymphohistiocytosis / macrophage activation syndrome (HLH/MAS) or HLH-like syndrome.
  13. Active bacterial, viral (including EBV infections), fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) requiring systemic therapy or antibiotics within 2 weeks prior to randomisation. COVID-19 infection needs to resolve to Grade ≤1 before commencing on treatment.
  14. infection unless:

    1. Patients with an HIV infection who are on effective anti-retroviral therapy with undetectable viral load within 6 months prior to trial entry are eligible for this trial.
    2. HIV RNA will be monitored during the trial as clinically indicated.
  15. Active infection (defined as the presence of detectable HBV DNA or HBs antigen).

    1. Patients who are HBcAb positive but are HBV DNA and HBsAg negative are eligible.
    2. If receiving surovatamig or rituximab, patients with HBcAb positive will have 12 weekly monitoring of HBV DNA for the duration of treatment and for 12 months following last dose of either therapy. These patients will receive appropriate anti-viral prophylaxis, with entecavir or similar, according to advice from the infectious disease service.
    3. Patients who are HBcAb positive and received ISRT alone do not require HBV DNA monitoring.
    4. Please note that patients who have received IVIG may have false positive HBcAb results. In such patients, if HBV DNA and HBsAg are negative, prophylaxis may be omitted if felt un-necessary by the infectious disease service, but monitoring of HBV DNA levels is still required.
  16. Active , defined by the detection of hepatitis C RNA in plasma by PCR. Patients who have received treatment for hepatitis C that was intended to eradicate the virus may participate if hepatitis C RNA levels are undetectable.
  17. Received a live, attenuated vaccine within 28 days prior to initiation of trial treatment. Examples of include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg. FluMist) are live, attenuated vaccines and are not allowed. Experimental and/or non-authorized SARS-CoV-2 vaccinations are not allowed.

    a. NOTE: Patients should not receive live vaccine while receiving trial intervention and for a period of at least 6 months after the last dose of surovatamig or rituximab, and until B-cell recovery within a normal range is confirmed.

  18. Active TB or history of completed treatment for active TB within the past 12 months - Note: IGRA testing must be performed if active or latent TB is suspected (e.g., clinical signs and symptoms of TB, contact history, or if the subject lives in or has travelled to or lived in the WHO high TB burden countries). For subjects with positive IGRA, active pulmonary TB must be excluded with clinical evaluation and radiologic imaging. Subjects with positive IGRA and no evidence of active disease may be enrolled after treatment for latent TB infection (recommend isoniazid monotherapy for a total of 6 months) has been initiated.
  19. History of clinically significant medical conditions, psychiatric conditions or any other reason that the investigator determines would:

    1. Interfere with individual participation in this trial OR
    2. Places the patient at an unacceptably high risk for toxicities OR
    3. Would make the patient an unsuitable candidate to receive trial therapy OR
    4. could interfere with evaluation of the trial intervention or interpretation of patient safety or trial results
  20. Participation in another clinical trial (for a separate medical comorbidity) with an product administered within the last 28 days or 5 half-lives (of that agent), whichever shorter
  21. Female patient who is pregnant or breastfeeding or is considering becoming pregnant or donating eggs during the trial or for approximately 12 months after the last dose of trial therapy.
  22. Male patients who are considering fathering a child or donating sperm during the trial or for approximately 12 months after the last dose of trial therapy.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Arm A (Investigational arm): Surovatamig

    This arm involves treatment with Surovatamig only with no radiotherapy. Treatment is in 3 phases. 1. Cycle 1 is a 14 day cycle including a triple step-up dosing: Day 1 of cycle 1: 0.09 mg, Day 4 of cycle 1: 0.27 mg, Day 8 of cycle 1: 1.0 mg. 2. Cycle 2-4 are 28 day cycles with a dose administered every 2 weeks: Cycles 2-4 (28-day cycle): Surovatamig treatment doses administered on days 1 and 15 of each cycle at 7.2mg. 3\. At the end of cycle 4, patients will enter the post-treatment period.

    Drug: Surovatamig

  • Active comparator
    Arm B1: Involved-Site Radiotherapy (ISRT) 24Gy

    This arm is the standard of care (SOC): Involved-Site Radiotherapy (ISRT) at 24Gy and involves radiotherapy for 3 weeks.

    Radiation: Involved Site Radiotherapy (ISRT)

  • Active comparator
    Arm B2: Involved-Site Radiotherapy (ISRT) 24Gy + rituximab x 6 cycles

    This arm is another standard of care (SOC): Involved-Site Radiotherapy (ISRT) at 24Gy with 6 doses of rituximab administered weekly by intravenous (IV) at 375 mg/m\^2. 1 week = 1 cycle.

    Radiation: Involved-Site Radiotherapy (ISRT) + Rituximab

Interventions

  • Surovatamig is supplied as a concentrate for solution for intravenous administration (2mg/mL).

  • RadiationInvolved Site Radiotherapy (ISRT)

    24 Gray of ISRT

  • RadiationInvolved-Site Radiotherapy (ISRT) + Rituximab

    Involved-Site Radiotherapy (ISRT) at 24Gy with 6 doses of rituximab administered weekly by intravenous (IV) at 375 mg/m\^2. 1 week = 1 cycle.

06

What researchers measure

Primary outcomes

  1. Event Free Survival

    Defined as death from any cause, failure to achieve complete response (CR) at End-of-Treatment ((EoT); defined as 18 weeks from start of treatment), initiation of new anti-lymphoma treatment (including new RT) or disease progression (based on Lugano 2014 Response Criteria), whichever comes first

    Time frame: Time from date of randomisation until disease progression until end of 5 year follow up.

  2. Event Free Survival

    As determined by the Lugano 2014 Response Criteria and audit of medical records

    Time frame: Time from date of randomisation to death from any cause, initiation of new anti-lymphoma treatment or disease progression until end of 10 year follow up. Assessment will be performed at end of treatment, every 3 months in year 1, every 6 months in year 2

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2035, 96 months later.

Of 35 non-industry phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 116. This study's planned 96 months is above that.

Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Jul 30, 2026
StartEst.
Jan 12, 2027
Primary completionEst.
Jan 13, 2035
CompletionEst.
Jan 13, 2035
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
138→140
Sep 30, 2026
Eligibility
16 inclusion criteria edited, 1 added, 2 removed; 23 exclusion criteria edited, 18 added, 4 removed
What changed in the criteria
Inclusion criteria
  • EditedPatients or their legally authorised representative must voluntarily sign and date an informed consent form (ICF), approved by a Human Research Ethics Committee (an HREC), prior to the initiation of any screening or trial- specific procedures.
  • RemovedProvide samples for optional genetic research that supports the Genomic Initiative.
  • EditedAge 18 years and older at the time of signing the informed consent form (ICF).
  • EditedMust have histologically confirmed classical follicular lymphoma (FL) (previously Grade 1 to 3a FL) at the most recent representative tumour biopsy based on the local pathology report, according to the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours (excluding cutaneous and duodenal FL).
  • EditedMust have Ann Arbor Stage I or II, nodal, non-bulky disease (maximum tumour diameter less than or equal to 7 cm≤7cm).
  • EditedA positron emission tomography/computed tomography (PET/CT) scan demonstrating PET-positive lesion(s), and
  • ChangedBefore At least one measurable nodal lesion (long axis over 1.5 cm) or at least one measurable extra-nodal lesion (long axis over 1.0 cm) on computed tomography (CT) scan or magnetic resonance imaging (MRI).Now ≥ 1 measurable nodal lesion (long axis > 1.5cm) on CT scan or MRI
  • EditedEastern Cooperative Oncology Group (ECOG) performance status 0-2.
  • EditedAbsolute neutrophil count (ANC) greater or equal toANC ≥ 1.0 ×x 10\^?9/L
  • RemovedHaemoglobin greater or equal to 8 g/dL
  • AddedHaemoglobin ≥ 90 g/L
  • EditedPlatelet count greater or equal to 75 ×≥ 100 x 10\^?9/L
  • EditedPatient must have adequate renal and liver function, unless values meeting the following criteria are related to lymphoma):
  • ChangedBefore Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) less or equal to 3.0 × upper limit of normal (ULN)Now Serum AST or ALT ≤ 3.0 × ULN
  • EditedTotal bilirubin less or equal toBilirubin ≤ 1.5 × ULN; subjects with Gilbert's syndrome may have total bilirubin greater thanlevels > 1.5 ×x ULN, but conjugated (direct) bilirubin must be less or equal to≤ 2 ×x ULN
  • EditedEstimated creatinine clearance (CrCl) greater or equal to 45CrCl ≥ 30 mL/min (as calculated by the Cockcroft-Gault formulaFormula)
  • EditedPatients of child-bearing potential must have a negative serum pregnancy test 10 to 14 days prior to randomisation and again within 24 hours prior to Cycle 1 Day 1 (C1D1)toC1D1. The pregnancy test must be sensitive to at least 25 mIU/mLml.
  • EditedWomen of child-bearingchildbearing potential must agree to practisepractice at least two2 protocol-specified methods of birth control, that are effective from 28 days prior to randomisation through at least 12 months after the last dose of trial drugtherapy. Female patients of non-child-bearingchildbearing potential do not need to use birth control.
  • EditedMale patients who are sexually active with female partnerspartner(s) of child-bearingchildbearing potential, must agree, from 28 days prior to randomisation through 12 months after the last dose of trial drugtherapy, to practisepractice the protocol-specified contraception, particularly using a latex or synthetic condom every time they have sexual intercourse with a partner of reproductive potential, even if they have undergone a successful vasectomy.
Exclusion criteria
  • EditedHas a history of prior systemic therapy or radiotherapy therapy for follicular lymphoma (FL).
  • EditedHas prior or current follicularFollicular large B-cell lymphoma (World Health Organization [WHO] 2022 classification), formerly follicularFollicular lymphoma Grade 3B (WHO 2016 classification), histologic transformation to diffuse large B-cell lymphoma (DLBCL) or other aggressive lymphomas.
  • AddedInadequately staged follicular lymphoma (unable to perform staging imaging or bone marrow trephine length totalling <20mm)
  • EditedKnown or suspected central nervous system (CNS) involvement at screening based on clinical presentation or imaging findings.
  • EditedAPrior exposure to surovatamig or a history of severe allergic or anaphylactic reactions to any component or excipient of AZD486.surovatamig
  • EditedHas had major surgery within 14 days prior to the first dose of trial intervention (excluding biopsies) orpr anticipation of the need for major surgery during trial intervention.
  • AddedRelative contraindications for radiotherapy
  • AddedNon-rheumatoid collagen vascular disorders involving the potential radiation field
  • AddedRadiation field that may impact on Cardiac implantable electronic devices (CIEDs).
  • AddedPrevious radiation therapy to the same site.
  • EditedMyocardial infarction within less or equal to≤ 12 weeks or stroke within 6 months prior to randomisation
  • EditedScreening 12-lead electrocardiogram (ECG) showing a baseline QT interval as corrected by Frederica's formula (QTcF) over> 480 msec
  • EditedHistory or presence of clinically relevant CNS pathology (which, based on investigatorInvestigator assessment) such as epilepsy, seizuremay prevent, paresislimit, or confound the protocol-specified assessments of neurotoxicity. This may include current seizure disorder requiring therapy, major cerebrovascular ischemia/haemorrhage, aphasia, severe brain injuries, severe dementia, severe Parkinson's disease, or cerebellar disease, organic brain syndrome, or psychosis.. Note: patients with history of seizure disorder must have complete CNS workup
  • EditedHistory of other prior malignancies, except defined low-risk cases.:
  • AddedMalignancy treated with curative intent and with no known active disease present for ≥2 years before the first dose of trial therapy and felt to be at low risk for recurrence by treating physician.
  • AddedAdequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
  • AddedAdequately treated carcinoma in situ without evidence of disease.
  • AddedLocalized prostate cancer, post-radical prostatectomy or with non-rising prostate-specific antigen levels < 0.1 ng/mL.
  • EditedCurrent autoimmune disease requiring immunosuppressive therapy other than prednisolone less than 20<10 mg daily (or equivalent).
  • RemovedCurrent seizure disorder requiring therapy (patients with history must have complete CNS workup).
  • RemovedHistory of clinically significant medical or psychiatric conditions interfering with trial participation or safety.

…and 24 more changes, on the record history on ClinicalTrials.gov ↗

Sep 30, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionEvent Free Survival: how it is measured was reworded
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Enrollment 138→140
    Eligibility 16 inclusion criteria edited, 1 added, 2 removed; 23 exclusion criteria edited, 18 added, 4 removed
    What changed in the criteria
    Inclusion criteria
    • EditedPatients or their legally authorised representative must voluntarily sign and date an informed consent form (ICF), approved by a Human Research Ethics Committee (an HREC), prior to the initiation of any screening or trial- specific procedures.
    • RemovedProvide samples for optional genetic research that supports the Genomic Initiative.
    • EditedAge 18 years and older at the time of signing the informed consent form (ICF).
    • EditedMust have histologically confirmed classical follicular lymphoma (FL) (previously Grade 1 to 3a FL) at the most recent representative tumour biopsy based on the local pathology report, according to the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours (excluding cutaneous and duodenal FL).
    • EditedMust have Ann Arbor Stage I or II, nodal, non-bulky disease (maximum tumour diameter less than or equal to 7 cm≤7cm).
    • EditedA positron emission tomography/computed tomography (PET/CT) scan demonstrating PET-positive lesion(s), and
    • ChangedBefore At least one measurable nodal lesion (long axis over 1.5 cm) or at least one measurable extra-nodal lesion (long axis over 1.0 cm) on computed tomography (CT) scan or magnetic resonance imaging (MRI).Now ≥ 1 measurable nodal lesion (long axis > 1.5cm) on CT scan or MRI
    • EditedEastern Cooperative Oncology Group (ECOG) performance status 0-2.
    • EditedAbsolute neutrophil count (ANC) greater or equal toANC ≥ 1.0 ×x 10\^?9/L
    • RemovedHaemoglobin greater or equal to 8 g/dL
    • AddedHaemoglobin ≥ 90 g/L
    • EditedPlatelet count greater or equal to 75 ×≥ 100 x 10\^?9/L
    • EditedPatient must have adequate renal and liver function, unless values meeting the following criteria are related to lymphoma):
    • ChangedBefore Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) less or equal to 3.0 × upper limit of normal (ULN)Now Serum AST or ALT ≤ 3.0 × ULN
    • EditedTotal bilirubin less or equal toBilirubin ≤ 1.5 × ULN; subjects with Gilbert's syndrome may have total bilirubin greater thanlevels > 1.5 ×x ULN, but conjugated (direct) bilirubin must be less or equal to≤ 2 ×x ULN
    • EditedEstimated creatinine clearance (CrCl) greater or equal to 45CrCl ≥ 30 mL/min (as calculated by the Cockcroft-Gault formulaFormula)
    • EditedPatients of child-bearing potential must have a negative serum pregnancy test 10 to 14 days prior to randomisation and again within 24 hours prior to Cycle 1 Day 1 (C1D1)toC1D1. The pregnancy test must be sensitive to at least 25 mIU/mLml.
    • EditedWomen of child-bearingchildbearing potential must agree to practisepractice at least two2 protocol-specified methods of birth control, that are effective from 28 days prior to randomisation through at least 12 months after the last dose of trial drugtherapy. Female patients of non-child-bearingchildbearing potential do not need to use birth control.
    • EditedMale patients who are sexually active with female partnerspartner(s) of child-bearingchildbearing potential, must agree, from 28 days prior to randomisation through 12 months after the last dose of trial drugtherapy, to practisepractice the protocol-specified contraception, particularly using a latex or synthetic condom every time they have sexual intercourse with a partner of reproductive potential, even if they have undergone a successful vasectomy.
    Exclusion criteria
    • EditedHas a history of prior systemic therapy or radiotherapy therapy for follicular lymphoma (FL).
    • EditedHas prior or current follicularFollicular large B-cell lymphoma (World Health Organization [WHO] 2022 classification), formerly follicularFollicular lymphoma Grade 3B (WHO 2016 classification), histologic transformation to diffuse large B-cell lymphoma (DLBCL) or other aggressive lymphomas.
    • AddedInadequately staged follicular lymphoma (unable to perform staging imaging or bone marrow trephine length totalling <20mm)
    • EditedKnown or suspected central nervous system (CNS) involvement at screening based on clinical presentation or imaging findings.
    • EditedAPrior exposure to surovatamig or a history of severe allergic or anaphylactic reactions to any component or excipient of AZD486.surovatamig
    • EditedHas had major surgery within 14 days prior to the first dose of trial intervention (excluding biopsies) orpr anticipation of the need for major surgery during trial intervention.
    • AddedRelative contraindications for radiotherapy
    • AddedNon-rheumatoid collagen vascular disorders involving the potential radiation field
    • AddedRadiation field that may impact on Cardiac implantable electronic devices (CIEDs).
    • AddedPrevious radiation therapy to the same site.
    • EditedMyocardial infarction within less or equal to≤ 12 weeks or stroke within 6 months prior to randomisation
    • EditedScreening 12-lead electrocardiogram (ECG) showing a baseline QT interval as corrected by Frederica's formula (QTcF) over> 480 msec
    • EditedHistory or presence of clinically relevant CNS pathology (which, based on investigatorInvestigator assessment) such as epilepsy, seizuremay prevent, paresislimit, or confound the protocol-specified assessments of neurotoxicity. This may include current seizure disorder requiring therapy, major cerebrovascular ischemia/haemorrhage, aphasia, severe brain injuries, severe dementia, severe Parkinson's disease, or cerebellar disease, organic brain syndrome, or psychosis.. Note: patients with history of seizure disorder must have complete CNS workup
    • EditedHistory of other prior malignancies, except defined low-risk cases.:
    • AddedMalignancy treated with curative intent and with no known active disease present for ≥2 years before the first dose of trial therapy and felt to be at low risk for recurrence by treating physician.
    • AddedAdequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • AddedAdequately treated carcinoma in situ without evidence of disease.
    • AddedLocalized prostate cancer, post-radical prostatectomy or with non-rising prostate-specific antigen levels < 0.1 ng/mL.
    • EditedCurrent autoimmune disease requiring immunosuppressive therapy other than prednisolone less than 20<10 mg daily (or equivalent).
    • RemovedCurrent seizure disorder requiring therapy (patients with history must have complete CNS workup).
    • RemovedHistory of clinically significant medical or psychiatric conditions interfering with trial participation or safety.

    …and 24 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionEvent Free Survival: how it is measured was reworded
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07736950
Lead sponsor
Australasian Leukaemia and Lymphoma Group
Responsible party
Sponsor
First posted
Jul 30, 2026
Start date
Jan 12, 2027 (estimated)
Primary completion
Jan 13, 2035 (estimated)
Completion
Jan 13, 2035 (estimated)
Last update
Sep 30, 2026

Study contacts

Chan Cheah
principal investigator · Sir Charles Gairdner Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Surovatamig

Start the discussion